#USA #Boston #EMFACE® #BTL Industries #TMJ Dysfunction

BTL Industries Expands EMFACE® Indications with TMJ Dysfunction FDA Clearance

In an important development for the medical and wellness technology sectors, BTL Industries has expanded the FDA-approved applications of its innovative EMFACE® platform to include treatment for temporomandibular joint (TMJ) dysfunction. This new clearance comes as part of BTL's continuous commitment to enhancing patient care through technology.

What is EMFACE®?

EMFACE® is a unique modality that combines synchronized radiofrequency and HIFES® technology aimed at facial muscle stimulation. Historically, treatments related to TMJ dysfunction have been limited, often requiring surgical options or invasive procedures. However, with the introduction of EMFACE®, patients now have access to a non-invasive alternative that significantly reduces discomfort and improves overall function.

David Chmel, CEO of BTL Industries, expressed enthusiasm about this new indication, stating, "EMFACE is an established technology platform with multiple FDA-cleared uses. This new indication allows dental, oral health, and wellness providers to address TMJ dysfunction within its approved uses, expanding the benefits of EMFACE to more patients."

Understanding TMJ Dysfunction

TMJ dysfunction is a common disorder affecting many individuals around the globe. It can manifest through a variety of symptoms such as jaw pain, frequent headaches, and difficulties with chewing or yawning. Often understated, these symptoms can severely impact the quality of life for those affected. Shireen Dhanani, DMD, from Leesburg, FL, noted, "TMJ dysfunction impacts more than the jaw — it affects quality of life. With EMFACE, we can now offer an accessible, non-invasive option that not only helps patients find relief and functional improvement, but also expands the scope of dental care."

How EMFACE® Works

The EMFACE® technology works by delivering a synchronized combination of radiofrequency energy and electrical stimulation to the facial muscles. This approach not only aids in relieving symptoms associated with TMJ dysfunction but also encourages muscle re-education and improves local blood circulation. Consequently, patients can experience improvements in their range of motion, helping them return to normal activities with less discomfort.

This groundbreaking technology, developed over years of research and engineering, allows for effective treatment without the need for surgeries, invasive injections, or drug therapies. As a non-surgical treatment option, EMFACE® stands out in its ability to deliver results efficiently.

Expanding Patient Care with Science-Backed Technology

BTL Industries has taken significant strides to redefine what is possible in facial care and wellness. The addition of TMJ dysfunction treatment to the EMFACE® platform serves as a testament to the company's commitment to bringing science-backed technologies to new medical areas. As more healthcare providers incorporate EMFACE® into their practices, the potential benefits for patients continue to grow.

Conclusion

BTL's EMFACE® represents a new frontier in patient solutions for TMJ dysfunction, allowing healthcare professionals to deliver innovative treatments that can significantly improve the quality of life for their patients. With this new FDA clearance, an increasing number of patients will have access to this cutting-edge technology, showcasing BTL Industries' commitment to advancing health care worldwide. For more insights and details about EMFACE®, visit www.emface.com.

About BTL Industries

Founded in 1993, BTL Industries is a leading global provider of medical devices, continuously supplying innovative solutions across various medical fields, including dermatology, orthopedics, and dental care. Operating in over 90 countries and boasting more than 200 patents, BTL employs over 500 research and development engineers focused on transforming medical treatments through technology and science. Its prominent products include EMSCULPT NEO®, EMSELLA®, and now, EMFACE®.